RNA Analytical/Quality Videos

31. Don't Forget These Important Points When Selecting An RNA CDMO 8/22/2024

    Together, Omega’s Jeff Atkinson & Sail Biomedicines’ Jim Nolan share their perspectives on the health of the linear mRNA and circRNA outsourcing sector.

32. The Make-or-Break Quality Attributes of Plasmid DNA 10/15/2025

    We all know that plasmid quality is foundational in dictating the quality of the final mRNA drug substance. In this clip homing in on upstream process considerations, speakers Stu Sundseth (Tune Therapeutics), Marc Wolfgang (Sail Biomedicines), and Christian Dohmen (Ethris) outline some of the most important CQAs for plasmids and the impact they can have on the resulting quality of the mRNA drug substance for linear mRNA. 

33. The Evolutions Of mRNA Analytical Development (So Far) 8/22/2024

    Linear mRNA analytical development has been rapidly advancing in the past few years and this panel discussion explores some of the biggest changes we’ve seen in the linear mRNA analytical paradigm.

34. Crafting A "Durable" Partnership: A Two-Pronged Approach

    Featured speakers for the "Got Raw Materials? The State Of The mRNA Supply Chain" event share how they are working to deepen their partnerships today.

35. In Which Specific Areas Do mRNA Makers Need More Regulatory Guidance? 5/10/2024

    Experts from this Advancing RNA Live panel discuss the results from a poll question revealing the top three areas RNA industry experts would be most interested in seeing additional mRNA-specific guidance from regulatory agencies.

36. Goldilocks & The Guidances: Finding "Just Right" For RNA Regulations 6/24/2025

    Do we need more specific regulatory guidance for every RNA modality and therapeutic approach? We asked and the Advancing RNA Live audience answered… Here, panelists Tiffany Lucas and Ulrike Jägle address the audience’s responses, as well as share their thoughts on just how prescriptive the future of regulatory guidance for RNA therapeutics approaches could/should be..

37. Where Does The mRNA Vaccine Regulatory Paradigm Fall Short For Therapeutics? 5/10/2024

    This Advancing RNA panel of experts sees a couple of important questions those striving to make RNA therapeutics will find themselves confronting when collaborating with regulators.

38. Bioinformatics In mRNA Development: Classification And Integration Conundrums 6/24/2025

    As both Advancing RNA Live speakers point out in this segment, the MHRA guidance focuses deeply on the critical role bioinformatics and AI/ML approaches will play in the development of personalized immunotherapies. Here, Eliquent Life Sciences’ Tiffany Lucas and CureVac’s Ulrike Jägle address the biggest challenges they anticipate companies will face in meeting the agencies’ recommendations.

39. Why We Still Haven't Solved mRNA Scale-Up 10/15/2025

    While we can make lots of mRNA at a smaller scale, when it comes to scaling up to kg quantities of mRNA, our current batch processes leave a lot to be desired. Together, Stu Sundseth of Tune Therapeutics and Christian Dohmen of Ethris unpack the biggest barriers to scaling IVT to achieve the desired yield and quality of mRNA, offering their take on how the field is innovating to overcome these issues. 

40. What Does 2025 (And Beyond) Hold For The RNA-LNP Space? 12/4/2024

    Three LNP experts share their thoughts on the incremental advancements they’d like to see the RNA-LNP space make in the next few years.